Sahajanand Medical Technologies Limited
16
6
6
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
12.5%
2 terminated/withdrawn out of 16 trials
77.8%
-8.7% vs industry average
31%
5 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
Role: collaborator
CRUZ Tunisia-Multivessel Registry
Role: lead
Hydra Registry - Italy Experience
Role: lead
Hydra Registry - UK
Role: lead
Hydra Single-centre Experience - Copenhagen, Denmark
Role: lead
S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System
Role: lead
Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA
Role: collaborator
A Safety and Efficacy of Supralimus™ Core™ Sirolimus Eluting Stent at MAX DDHV Institute
Role: lead
Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population
Role: collaborator
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent
Role: lead
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
Role: collaborator
Per-cutaneous Intervention Based Paclitaxel and Sirolimus-Eluting Versus Bare Stents for the Treatment of de Novo Coronary Lesions (PAINT)
Role: lead
Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions
Role: lead
SERIES III RUN-IN Clinical Trial: A Comparison of the Supralimus® Stent With the Xience V™ Stent
Role: lead
The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions
Role: lead
Supralimus-Core™ Pharmacokinetic (PK) Study
Role: lead
All 16 trials loaded